Sign inJoin waitlistJoin the waitlist

Edward Garon

Director, UCLA Thoracic Oncology Program · UCLA

Credentials: · · · ·

History

Hematology and Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
2003–2006
Internal Medicine
University of Chicago Medical Center
1999–2000
UCLA
Washington University School of Medicine
1995–1999

Research

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Science · 2015 · 6,657 citations
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 5,534 citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2016 · Last of 19 authors · 5,414 citations

Jonathan Goldman
35 papers
Steven Dubinett
30 papers
Aaron Lisberg
28 papers
RH
Roy Herbst
17 papers
Amy Cummings
16 papers
Jay Lee
14 papers · 1 as a fellow
MJ
Melissa Johnson
14 papers
MH
Matthew Hellmann
13 papers · 2 as a fellow
JC
James Carroll
11 papers
Maria Velez
10 papers · 8 as a fellow
Marina Garassino
10 papers
NR
Naiyer Rizvi
10 papers

Grants

HLA B44 Motif Neoepitopes in NSCLC: Evaluating Their Effects on the TME and Adding Them to Established Markers in a Model to Predict Durable Benefit from PD- 1 Inhibition with and Without Chemotherapy
National Cancer Institute · R01
Contact PI · $2.9M · University of California Los Angeles
2023–2028
Evaluation of a Therapeutic Vaccination Strategy with Motif Neoepitope Peptide-Pulsed Autologous Dendritic Cells for Non-Small Cell Lung Cancer Patients Harboring a Charged HLA-B Binding Pocket.
National Cancer Institute · R21
Contact PI · $393.3K · University of California Los Angeles
2023–2025
A Model for Predicting Response to PD-1 Inhibitors in NSCLC
National Cancer Institute · R01
Contact PI · $3.2M · University of California Los Angeles
2017–2021
Inhibiting EGFR and ER Pathways in NSCLC
National Cancer Institute · K23
Contact PI · $826.2K · University of California Los Angeles
2011–2016

Clinical trials

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 1
Jonsson Comprehensive Cancer Center
2019–2027
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Principal investigator · Completed · Phase 1
Dynavax Technologies Corporation
2017–2019
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Jonsson Comprehensive Cancer Center
2016–2019
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
Principal investigator · Withdrawn · Phase 1
Jonsson Comprehensive Cancer Center
2016–2019